Cancer became undetectable in 1 out of 12 patients
In a trial with 61 patients with advanced pancreatic cancer, the drug daraxonrasib rendered tumors undetectable or stopped growth in one out of every twelve participants. While doctors state it is not a cure, the treatment offers hope given that only about 3% of patients with metastatic disease survive five years.
- Field
- cancer research
- What they did
- Researchers tested the drug daraxonrasib on patients with metastatic pancreatic cancer and found that in 1 out of 12 cases the tumor became undetectable, and in almost all other cases it stopped growing.
- Why it matters
- This is important because the five-year survival rate for this cancer is only about 3%, and the new treatment could extend patients' lives even if it does not achieve a full cure.
#pancreatic cancer#daraxonrasib#clinical trial#survival rate#oncology



